난소암 진단에서 Human Epididymis Protein 4의 유용성 및 한국인의 정상 참고범위

키워드

참고문헌 (33)

1. "Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No . 11" (2013)[URL]
2. "National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up", Gynecol Oncol, 55, pp.S4~S14 (1994)
3. Kirchhoff C, "A major human epididymisspecific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors", Biol Reprod, 45, pp.350~357 (1991)
4. Schummer M, "Comparative hybridization of an array of 21,500 ovar-ian cDNAs for the discovery of genes overexpressed in ovarian carcinomas", Gene, 238, pp.375~385 (1999)
5. Hellström I, "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma", Cancer Res, 63, pp.3695~3700 (2003)
6. Hallamaa M, "Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women", Gynecol Oncol, 125, pp.667~672 (2012)
7. Lin J, "Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis", Eur J Obstet Gynecol Reprod Biol, 167, pp.81~85 (2013)
8. Drapkin R, "Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas", Cancer Res, 65, pp.2162~2169 (2005)
9. Iwahori K, "Serum HE4 as a diagnostic and prognostic marker for lung cancer", Tumour Biol, 33, pp.1141~1149 (2012)
10. Escudero JM, "Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases", Clin Chem, 57, pp.1534~1544 (2011)
11. Nagy B Jr, "Elevated human epididymis protein 4 concentrations in chronic kidney disease", Ann Clin Biochem, 49, pp.377~380 (2012)
12. Hertlein L, "Human epididymis protein 4 (HE4) in benign and malignant diseases", Clin Chem Lab Med, 50, pp.2181~2188 (2012)
13. Moore RG, "Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age", Am J Obstet Gynecol, 206, pp.349~ (2012)
14. Lowe KA, "Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer", Cancer Epidemiol, Biomarkers Prev, 17, pp.2480~2487 (2008)
15. Moore RG, "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass", Gynecol Oncol, 108, pp.402~408 (2008)
16. Nolen B, "Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass", Gynecol Oncol, 117, pp.440~445 (2010)
17. Montagnana M, "The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?", Clin Chem Lab Med, 49, pp.521~525 (2011)
18. Kalapotharakos G, "High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer", J Ovarian Res, 5, pp.20~ (2012)
19. Steffensen KD, "Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients", Int J Gynecol Cancer, 21, pp.1040~1047 (2011)
20. Trudel D, "Human epididymis protein 4 (HE4) and ovarian cancer prognosis", Gynecol Oncol, 127, pp.511~515 (2012)
21. Schummer M, "Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125", Gynecol Oncol, 125, pp.65~69 (2012)
22. Moore RG, "Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass", Obstet Gynecol, 118, pp.280~288 (2011)
23. Moore RG, "A novel multiple marker bioassay utilizing HE4 and CA125for the prediction of ovarian cancer in patients with a pelvic mass", Gynecol Oncol, 112, pp.40~46 (2009)
24. Chan KK, "The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass", Gynecol Oncol, 128, pp.239~244 (2013)
25. Ruggeri G, "HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm", Clin Chim Acta, 412, pp.1447~1453 (2011)
26. Van Gorp T, "HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm", Br J Cancer, 104, pp.863~870 (2011)
27. Chudecka-Glaz AM, "ROMA, an algorithm for ovarian cancer", Clin Chim Acta, 440, pp.143~151 (2015)
28. Paulsen T, "Improved shortterm survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals", Int J Gynecol Cancer, 16(Suppl 1), pp.11~17 (2006)
29. Jacobs I, "A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer", Br J Obstet Gynaecol, 97, pp.922~929 (1990)
30. Bast RC Jr, "Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers", Int J Gynecol Cancer, 22(Suppl 1), pp.S5~S8 (2012)
31. Jacob F, "No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting", Gynecol Oncol, 121, pp.487~491 (2011)
32. Kaijser J, "A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass", Gynecol Oncol, 129, pp.377~383 (2013)
33. Yang J, "The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay", Clin Biochem, 46, pp.1705~1708 (2013)

관련 논문AI추천